Pregnancy: Category B: Doripenem was not teratogenic and did not produce effects on ossification, developmental delays or fetal weight following intravenous administration during organogenesis at doses as high as 1 g/kg/day in rats and 50 mg/kg/day in rabbits. There are no adequate and well-controlled studies in pregnant women. Doripenem should only be considered if the benefit to the mother outweighs the risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Caution should be exercised when doripenem is administered to a nursing woman.